Concurrent Waldenstrom Macroglobulinemia and Mutant Transthyretin Cardiac Amyloidosis

Authors

Xiaoxiao Qian, Department of Cardiology, Inova Heart and Vascular Institute, Falls Church, Virginia, USAFollow
Hooman Bakhshi, Departemt of Cardiology, Inova Heart and Vascular Institute, Falls Church, Virginia, USA
Rakesh Biswas, Departemt of Hematology and Oncology, Inova Fairfax Hospital, Falls Church, Virginia,
Raghav Gattani, Departemt of Cardiology, Inova Heart and Vascular Institute, Falls Church, Virginia,
Jamie L Kennedy, Department of Advanced Heart Failure and Transplant, Inova Heart and Vascular Institute, Falls Church, Virginia,

Abstract

Cardiac amyloidosis is caused by abnormal deposit of amyloid in the myocardium and can be divided into light chain (AL) amyloidosis and transthyretin (ATTR) amyloidosis. ATTR amyloidosis can be further divided into wild-type and mutant type based on genetic mutation. Differentiation between AL, wild-type, and mutant type ATTR amyloidosis has significant prognostic and therapeutic implications.

Recommended Citation

Qian, Xiaoxiao; Bakhshi, Hooman; Biswas, Rakesh; Gattani, Raghav; and Kennedy, Jamie L (2022) "Concurrent Waldenstrom Macroglobulinemia and Mutant Transthyretin Cardiac Amyloidosis," Journal of Community Hospital Internal Medicine Perspectives: Vol. 12: Iss. 6, Article 15.
DOI: 10.55729/2000-9666.1117
Available at: https://scholarlycommons.gbmc.org/jchimp/vol12/iss6/15